Indacaterol/glycopyrronium bromide: Phase III data

Top-line data from the double-blind, international Phase III SPARK trial in 2,224 patients with severe to very severe COPD showed that once-daily QVA149 met the primary endpoint of reducing the rate of moderate to severe COPD exacerbations from baseline to week 64 vs.

Read the full 433 word article

User Sign In